Nuvalent (NUVL) Cash from Financing Activities (2020 - 2026)
Nuvalent (NUVL) posted Cash from Financing Activities of $9.8 million for Q1 2026, down 98.04% on a QoQ basis from $500.3 million in Q4 2025, and up 115.5% year-over-year from $4.5 million in Q1 2025.
Nuvalent (NUVL) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Nuvalent's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $9.8 million for Q1 2026.
- Quarterly Cash from Financing Activities rose 115.5% year-over-year to $9.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $520.6 million (down 8.26% YoY) and the FY2025 annual result came in at $515.3 million, down 9.41% from the prior year.
- Cash from Financing Activities was $9.8 million for Q1 2026 at Nuvalent, down from $500.3 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $550.3 million in Q3 2024 and bottomed at -$768000.0 in Q1 2022.
- A 5-year average of $98.8 million and a median of $4.8 million in 2025 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities plunged 107.68% — and 2024, when it jumped 35311.76%.
- Nuvalent's Cash from Financing Activities stood at $248.7 million in 2022, then soared by 34.08% to $333.4 million in 2023, then slumped by 97.45% to $8.5 million in 2024, then jumped by 5791.0% to $500.3 million in 2025, then tumbled by 98.04% to $9.8 million in 2026.
- Business Quant data shows NUVL's Cash from Financing Activities at $9.8 million in Q1 2026, $500.3 million in Q4 2025, and $4.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | 9.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.80 Mn |
| Mar 31, 2026 | 9.80 Mn |
| Dec 31, 2025 | 500.26 Mn |
| Dec 31, 2025 | 500.26 Mn |
| Sep 30, 2025 | 4.77 Mn |
| Sep 30, 2025 | 4.77 Mn |
| Jun 30, 2025 | 5.76 Mn |
| Jun 30, 2025 | 5.76 Mn |
| Mar 31, 2025 | 4.55 Mn |
| Mar 31, 2025 | 4.55 Mn |
| Dec 31, 2024 | 8.49 Mn |
| Dec 31, 2024 | 8.49 Mn |
| Sep 30, 2024 | 550.27 Mn |
| Sep 30, 2024 | 550.27 Mn |
| Jun 30, 2024 | 4.14 Mn |
| Jun 30, 2024 | 4.14 Mn |
| Mar 31, 2024 | 5.99 Mn |
| Mar 31, 2024 | 5.99 Mn |
| Dec 31, 2023 | 333.42 Mn |
| Dec 31, 2023 | 333.42 Mn |